NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intra-Cellular Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.51 -0.10 (-0.42 %) (As of 01/27/2020 02:37 PM ET) Add Compare Today's Range$22.44Now: $23.51▼$24.0950-Day Range$10.20MA: $23.85▼$38.4952-Week Range$6.75Now: $23.51▼$43.56Volume29,620 shsAverage Volume2.34 million shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITCI Previous Symbol CUSIPN/A CIK1567514 Webhttp://www.intracellulartherapies.com/ Phone646-440-9333Debt Debt-to-Equity Ratio0.09 Current Ratio7.77 Quick Ratio7.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$250,000.00 Price / Sales5,211.70 Cash FlowN/A Price / Cash FlowN/A Book Value$5.81 per share Price / Book4.05Profitability EPS (Most Recent Fiscal Year)($2.84) Net Income$-155,130,000.00 Net MarginsN/A Return on Equity-54.27% Return on Assets-45.84%Miscellaneous Employees73 Outstanding Shares55,420,000Market Cap$1.30 billion Next Earnings Date2/26/2020 (Estimated) OptionableOptionable Receive ITCI News and Ratings via Email Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ITCI Rates by TradingView Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions What is Intra-Cellular Therapies' stock symbol? Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI." How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies Inc (NASDAQ:ITCI) posted its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History. When is Intra-Cellular Therapies' next earnings date? Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies. What price target have analysts set for ITCI? 8 brokerages have issued twelve-month price targets for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they expect Intra-Cellular Therapies' stock price to reach $36.57 in the next year. This suggests a possible upside of 55.9% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies. What is the consensus analysts' recommendation for Intra-Cellular Therapies? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies. What are Wall Street analysts saying about Intra-Cellular Therapies stock? Here are some recent quotes from research analysts about Intra-Cellular Therapies stock: 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (1/14/2020) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $26 price target on ITCI shares. Intra-Cellular reported 1Q19 financial performance, ending the period with cash of $312.8M. Our model projects sufficient funding into 2H20 and through several clinical and regulatory milestones including NDA acceptance/approval of lumateperone for schizophrenia and P3 data in bipolar depression (Studies 401 & 404) that are expected later this quarter. We also look forward to luma’s potential approval in 3Q19, the establishment of the company’s commercial team and its market launch as a differentiated, broadly active neuropsych product." (5/8/2019) Has Intra-Cellular Therapies been receiving favorable news coverage? Headlines about ITCI stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Intra-Cellular Therapies. Are investors shorting Intra-Cellular Therapies? Intra-Cellular Therapies saw a drop in short interest in January. As of January 15th, there was short interest totalling 8,370,000 shares, a drop of 34.9% from the December 31st total of 12,850,000 shares. Based on an average daily volume of 2,680,000 shares, the short-interest ratio is presently 3.1 days. Currently, 17.9% of the shares of the stock are short sold. View Intra-Cellular Therapies' Current Options Chain. Who are some of Intra-Cellular Therapies' key competitors? Some companies that are related to Intra-Cellular Therapies include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC) and PTC Therapeutics (PTCT). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), AbbVie (ABBV), Myovant Sciences (MYOV), GW Pharmaceuticals PLC- (GWPH) and Zynerba Pharmaceuticals (ZYNE). Who are Intra-Cellular Therapies' key executives? Intra-Cellular Therapies' management team includes the folowing people: Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)Mr. Lawrence J. Hineline CPA, Sr. VP of Fin., CFO, Treasurer and Assistant Sec. (Age 63)Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64) Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (1.61%), Rhenman & Partners Asset Management AB (0.90%), First Midwest Bank Trust Division (0.18%), Assenagon Asset Management S.A. (0.03%), Gainplan LLC (0.02%) and Janney Montgomery Scott LLC (0.01%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies. Which institutional investors are selling Intra-Cellular Therapies stock? ITCI stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Candriam Luxembourg S.C.A.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies. Which institutional investors are buying Intra-Cellular Therapies stock? ITCI stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Assenagon Asset Management S.A., Gainplan LLC, Janney Montgomery Scott LLC and Kistler Tiffany Companies LLC. View Insider Buying and Selling for Intra-Cellular Therapies. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Intra-Cellular Therapies' stock price today? One share of ITCI stock can currently be purchased for approximately $23.46. How big of a company is Intra-Cellular Therapies? Intra-Cellular Therapies has a market capitalization of $1.30 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies. What is Intra-Cellular Therapies' official website? The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/. How can I contact Intra-Cellular Therapies? Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected] MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 416 (Vote Outperform)Underperform Votes: 359 (Vote Underperform)Total Votes: 775MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: Which market index is the best?
